v3.25.3

Grant Agreements (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended
	Jan. 13, 2022	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accrued and other liabilities		$ 68,375		$ 68,375		$ 85,873
Vaccinal Antibody Grant \| Grant revenue
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Grant revenue		300	$ 1,600	1,700	$ 3,800
Vaccinal Antibody Grant \| Gates Foundation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock shares purchased (in shares)	881,365
Common stock, shares purchased price (in USD per share)	$ 45.38
Common stock, shares purchased, aggregate purchase price	$ 40,000
Common stock, shares issued, fair market value	$ 28,500
Closing stock price (in USD per share)	$ 37.65
Premium received	$ 11,300
Unused grant funds returned		9,500
Deferred revenue		9,400		9,400		11,100
Accrued and other liabilities		$ 2,100		$ 2,100		$ 11,600

Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.

+ References

No definition available.

+ Details

Name:	us-gaap_AccruedLiabilitiesAndOtherLiabilities
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Accounting Standards Codification
-Section 25
-Paragraph 2
-SubTopic 10
-Topic 470
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481174/470-10-25-2

+ Details

Name:	us-gaap_DeferredIncome
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue that is not accounted for under Topic 606.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

+ Details

Name:	us-gaap_RevenueNotFromContractWithCustomer
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Closing stock price

+ References

No definition available.

+ Details

Name:	vir_ClosingStockPrice
Namespace Prefix:	vir_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Unused Grant Funds Returned

+ References

No definition available.

+ Details

Name:	vir_CollaborativeArrangementUnusedGrantFundsReturned
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Common Stock, Shares Issued, Fair Market Value

+ References

No definition available.

+ Details

Name:	vir_CommonStockSharesIssuedFairMarketValue
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Common Stock, Shares Purchased

+ References

No definition available.

+ Details

Name:	vir_CommonStockSharesPurchased
Namespace Prefix:	vir_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Common Stock, Shares Purchased , Aggregate Purchase Price

+ References

No definition available.

+ Details

Name:	vir_CommonStockSharesPurchasedAggregatePurchasePrice
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Common Stock, Shares Purchased, Share Price

+ References

No definition available.

+ Details

Name:	vir_CommonStockSharesPurchasedSharePrice
Namespace Prefix:	vir_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Underlying shares, Premium received

+ References

No definition available.

+ Details

Name:	vir_UnderlyingSharesPremiumReceived
Namespace Prefix:	vir_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=vir_VaccinalAntibodyGrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_GrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=vir_GatesFoundationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Vir Biotechnology, Inc. 10-Q